Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 6/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.38 |
| ▸ | CPB1 | P15086 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23978678 | 1.00 | IDO1 (0.41) | IDO1DPP4DPP7KCNH2TSHR | |
| SCHEMBL30083829 | 1.00 | IDO1 (0.41) | IDO1DPP4DPP7KCNH2TSHR | |
| SCHEMBL23978680 | 0.89 | EPHX2 (0.39) | TSHREPHX2ALDH1A1FKBP1A | |
| SCHEMBL23978753 | 0.87 | KDM4C (0.39) | EPHX2ALDH1A1 | |
| SCHEMBL30279437 | 0.87 | KDM4C (0.39) | EPHX2ALDH1A1 | |
| SCHEMBL24803439 | 0.87 | KDM4C (0.39) | EPHX2ALDH1A1 | |
| SCHEMBL30083852 | 0.82 | SYK (0.43) | — | |
| SCHEMBL23978692 | 0.82 | SYK (0.43) | — | |
| SCHEMBL23978772 | 0.82 | EPHX2 (0.58) | IDO1TSHREPHX2ALDH1A1 | |
| SCHEMBL24803485 | 0.82 | EPHX2 (0.58) | IDO1TSHREPHX2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220411366-A1 | INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411366-A1 | INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF | ITGB1, ITGB2, ITGA2 | IDO1 2127/4885DPP4 1197/4885DPP7 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.